Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 1015-1018

  Yoon, Young Kyung ^a   Kim, Jeong Yeon ^a   Park, Dae Won ^a   Sohn, Jang Wook ^a   Kim, Min Ja ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Case control study; Minimum inhibitory concentration; Risk factors

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; HABEKACIN; LINEZOLID; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG MONITORING; HUMAN; KOREA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; BACTEREMIA; CASE CONTROL STUDY; FEMALE; ISOLATION AND PURIFICATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PROGNOSIS; RISK FACTOR; STAPHYLOCOCCUS INFECTION; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; KOREA; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 77953703747     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq050     Document Type: Article

References (10)

1. Fowler VG Jr, Olsen MK, Corey GR et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066-72.
2. Hawkins C, Huang J, Jin N et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007; 167: 1861-7.
3. Khatib R, Johnson LB, Sharma M et al. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis 2009; 41: 4-9.
4. Wang G, Hindler JF, Ward KW et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883-6.
5. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
6. Kim JY, Sohn JW, Park DW et al. Control of extended-spectrum β-lactamase-producing Klebsiella pneumoniae using a computerassisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 2008; 62: 416-21.
7. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M7-A8. CLSI, Wayne, PA, 2009.
8. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
9. Moellering RC Jr. New treatments for multiply drug-resistant Gram-positive bacteria. J Infect 2009; 59: 1-3.
10. Hsu DI, Hidayat LK, Quist R et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008; 32: 378-85.